Clinically significant interactions with antidepressants

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Depression is one of the most frequent and severe mental disorders, and concurrent medical conditions commonly coexist in depressed patients. This presents numerous potentials for interactions between antidepressants and other nonpsychotropics prescribed for the same patient. Many selective serotonin reuptake inhibitors and selective serotonin and norepinephrine reuptake inhibitors possess various extent of inhibition towards different cytochrome P-450 isoenzymes, which constitute the primary mechanism of reported antidepressant drug interactions in the literature. Most of the antidepressants are also metabolized by the cytochrome P-450 enzyme system. As such, modulation of their hepatic elimination can occur with concurrently administered substrates, inhibitors, or inducers of the same cytochrome P-450 isoenzyme. In addition, the basal enzyme activity and genetic polymorphism affecting specific cytochrome P-450 isoenzyme can affect the magnitude and clinical significance of the cytochrome P-450-mediated drugantidepressant interaction. In addition to drug-metabolizing enzymes, uptake and efflux drug transporters that are present at many biological membranes, including the blood-brain barrier, the intestinal epithelial cells, the hepatocytes, and the renal tubular cells, can also affect systemic exposure and central nervous system penetration of most antidepressants, and hence pharmacological response. Although cytochrome P-450- mediated drug interactions still constitute the majority of the reported literature data, more recent studies have focused on these drug transporters in mediating drug interactions, including the antidepressants. In contrast to pharmacokinetic interactions, pharmacodynamic drug interactions involving the antidepressants mostly are derived from case reports and less well documented. Nevertheless, the more relevant and clinically significant pharmacodynamic interactions will also be reviewed.

Original languageEnglish (US)
Title of host publicationApplied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents
PublisherSpringer International Publishing
Pages451-469
Number of pages19
ISBN (Electronic)9783319278834
ISBN (Print)9783319278810
DOIs
StatePublished - Jan 1 2016

Fingerprint

Antidepressive Agents
Cytochrome P-450 Enzyme System
Drug Interactions
Isoenzymes
Serotonin Uptake Inhibitors
Pharmaceutical Preparations
Genetic Polymorphisms
Enzymes
Blood-Brain Barrier
Mental Disorders
Hepatocytes
Central Nervous System
Pharmacokinetics
Epithelial Cells
Pharmacology
Depression
Kidney
Membranes

Keywords

  • Antidepressants
  • Cytochrome P-450
  • Monoamine oxidase inhibitors
  • Pharmacodynamics
  • Pharmacokinetics
  • Selective serotonin reuptake inhibitors
  • Serotonin-norepinephrine reuptake inhibitors
  • Transporters
  • Tricyclics

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Lam, Y. F. (2016). Clinically significant interactions with antidepressants. In Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents (pp. 451-469). Springer International Publishing. https://doi.org/10.1007/978-3-319-27883-4_18

Clinically significant interactions with antidepressants. / Lam, Yui-wing F.

Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Springer International Publishing, 2016. p. 451-469.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lam, YF 2016, Clinically significant interactions with antidepressants. in Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Springer International Publishing, pp. 451-469. https://doi.org/10.1007/978-3-319-27883-4_18
Lam YF. Clinically significant interactions with antidepressants. In Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Springer International Publishing. 2016. p. 451-469 https://doi.org/10.1007/978-3-319-27883-4_18
Lam, Yui-wing F. / Clinically significant interactions with antidepressants. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Springer International Publishing, 2016. pp. 451-469
@inbook{b9b65cc755114113bebece70f5925874,
title = "Clinically significant interactions with antidepressants",
abstract = "Depression is one of the most frequent and severe mental disorders, and concurrent medical conditions commonly coexist in depressed patients. This presents numerous potentials for interactions between antidepressants and other nonpsychotropics prescribed for the same patient. Many selective serotonin reuptake inhibitors and selective serotonin and norepinephrine reuptake inhibitors possess various extent of inhibition towards different cytochrome P-450 isoenzymes, which constitute the primary mechanism of reported antidepressant drug interactions in the literature. Most of the antidepressants are also metabolized by the cytochrome P-450 enzyme system. As such, modulation of their hepatic elimination can occur with concurrently administered substrates, inhibitors, or inducers of the same cytochrome P-450 isoenzyme. In addition, the basal enzyme activity and genetic polymorphism affecting specific cytochrome P-450 isoenzyme can affect the magnitude and clinical significance of the cytochrome P-450-mediated drugantidepressant interaction. In addition to drug-metabolizing enzymes, uptake and efflux drug transporters that are present at many biological membranes, including the blood-brain barrier, the intestinal epithelial cells, the hepatocytes, and the renal tubular cells, can also affect systemic exposure and central nervous system penetration of most antidepressants, and hence pharmacological response. Although cytochrome P-450- mediated drug interactions still constitute the majority of the reported literature data, more recent studies have focused on these drug transporters in mediating drug interactions, including the antidepressants. In contrast to pharmacokinetic interactions, pharmacodynamic drug interactions involving the antidepressants mostly are derived from case reports and less well documented. Nevertheless, the more relevant and clinically significant pharmacodynamic interactions will also be reviewed.",
keywords = "Antidepressants, Cytochrome P-450, Monoamine oxidase inhibitors, Pharmacodynamics, Pharmacokinetics, Selective serotonin reuptake inhibitors, Serotonin-norepinephrine reuptake inhibitors, Transporters, Tricyclics",
author = "Lam, {Yui-wing F}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-27883-4_18",
language = "English (US)",
isbn = "9783319278810",
pages = "451--469",
booktitle = "Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Clinically significant interactions with antidepressants

AU - Lam, Yui-wing F

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Depression is one of the most frequent and severe mental disorders, and concurrent medical conditions commonly coexist in depressed patients. This presents numerous potentials for interactions between antidepressants and other nonpsychotropics prescribed for the same patient. Many selective serotonin reuptake inhibitors and selective serotonin and norepinephrine reuptake inhibitors possess various extent of inhibition towards different cytochrome P-450 isoenzymes, which constitute the primary mechanism of reported antidepressant drug interactions in the literature. Most of the antidepressants are also metabolized by the cytochrome P-450 enzyme system. As such, modulation of their hepatic elimination can occur with concurrently administered substrates, inhibitors, or inducers of the same cytochrome P-450 isoenzyme. In addition, the basal enzyme activity and genetic polymorphism affecting specific cytochrome P-450 isoenzyme can affect the magnitude and clinical significance of the cytochrome P-450-mediated drugantidepressant interaction. In addition to drug-metabolizing enzymes, uptake and efflux drug transporters that are present at many biological membranes, including the blood-brain barrier, the intestinal epithelial cells, the hepatocytes, and the renal tubular cells, can also affect systemic exposure and central nervous system penetration of most antidepressants, and hence pharmacological response. Although cytochrome P-450- mediated drug interactions still constitute the majority of the reported literature data, more recent studies have focused on these drug transporters in mediating drug interactions, including the antidepressants. In contrast to pharmacokinetic interactions, pharmacodynamic drug interactions involving the antidepressants mostly are derived from case reports and less well documented. Nevertheless, the more relevant and clinically significant pharmacodynamic interactions will also be reviewed.

AB - Depression is one of the most frequent and severe mental disorders, and concurrent medical conditions commonly coexist in depressed patients. This presents numerous potentials for interactions between antidepressants and other nonpsychotropics prescribed for the same patient. Many selective serotonin reuptake inhibitors and selective serotonin and norepinephrine reuptake inhibitors possess various extent of inhibition towards different cytochrome P-450 isoenzymes, which constitute the primary mechanism of reported antidepressant drug interactions in the literature. Most of the antidepressants are also metabolized by the cytochrome P-450 enzyme system. As such, modulation of their hepatic elimination can occur with concurrently administered substrates, inhibitors, or inducers of the same cytochrome P-450 isoenzyme. In addition, the basal enzyme activity and genetic polymorphism affecting specific cytochrome P-450 isoenzyme can affect the magnitude and clinical significance of the cytochrome P-450-mediated drugantidepressant interaction. In addition to drug-metabolizing enzymes, uptake and efflux drug transporters that are present at many biological membranes, including the blood-brain barrier, the intestinal epithelial cells, the hepatocytes, and the renal tubular cells, can also affect systemic exposure and central nervous system penetration of most antidepressants, and hence pharmacological response. Although cytochrome P-450- mediated drug interactions still constitute the majority of the reported literature data, more recent studies have focused on these drug transporters in mediating drug interactions, including the antidepressants. In contrast to pharmacokinetic interactions, pharmacodynamic drug interactions involving the antidepressants mostly are derived from case reports and less well documented. Nevertheless, the more relevant and clinically significant pharmacodynamic interactions will also be reviewed.

KW - Antidepressants

KW - Cytochrome P-450

KW - Monoamine oxidase inhibitors

KW - Pharmacodynamics

KW - Pharmacokinetics

KW - Selective serotonin reuptake inhibitors

KW - Serotonin-norepinephrine reuptake inhibitors

KW - Transporters

KW - Tricyclics

UR - http://www.scopus.com/inward/record.url?scp=84978285312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978285312&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-27883-4_18

DO - 10.1007/978-3-319-27883-4_18

M3 - Chapter

AN - SCOPUS:84978285312

SN - 9783319278810

SP - 451

EP - 469

BT - Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents

PB - Springer International Publishing

ER -